Literature DB >> 31539757

The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.

Pedro De Marchi1, Matias E Melendez2, Ana C Laus2, Pamela A Kuhlmann2, Ana Carolina de Carvalho2, Lidia Maria R B Arantes2, Adriane F Evangelista2, Edilene S Andrade2, Gilberto de Castro3, Rui M Reis2, André Lopes Carvalho4, Luciano de Souza Viana5.   

Abstract

BACKGROUND: Induction chemotherapy in locally-advanced head and neck squamous cell carcinoma (LAHNSCC) patients is potentially associated to serious adverse events. Biomarkers associated with toxicity could tailor its indication. This study evaluated the association between single-nucleotide polymorphisms (SNPs) in metabolic genes and toxicity to induction chemotherapy.
METHODS: 59 LAHNSCC phase II clinical trial patients (NCT00959387) were assessed regarding 47 metabolic genes (366 SNPs). Toxicities were graded (CTCAE 3.0) and statistical analysis was performed.
RESULTS: The SNPs rs8187710 (ABCC2) and rs1801131 (MTHFR) were associated to increased risk of gastrointestinal toxicity, whereas the SNPs rs3788007 (ABCG1) and rs4148943 (CHST3) were associated to decreased risk. Two other SNPs, rs2301159 (SLC10A2) and rs2470890 (CYP1A2), were associated with increased risk of hematological toxicity. Nevertheless, these SNPs did not remain significant after adjusting for multiple comparisons.
CONCLUSIONS: This study could not demonstrate relationship between SNPs and toxicity to induction chemotherapy in LAHNSCC patients. The small number of patients may have affected the results.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Head and neck cancer; Induction chemotherapy; LAHNSCC; Pharmacogenomic; SNP; Toxicity

Year:  2019        PMID: 31539757     DOI: 10.1016/j.oraloncology.2019.09.013

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  Associations of the MTHFR rs1801133 polymorphism with gastric cancer risk in the Chinese Han population.

Authors:  Zhiqiang Han; Huaming Sheng; Qiuzhi Gao; Yu Fan; Xiang Xie
Journal:  Biomed Rep       Date:  2020-11-17

2.  Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma.

Authors:  Farshid Fathi; Batool Zamani; Ahmad Piroozmand; Samaneh Mozafarpoor; Effat Seyedhashemi; Reza ArefNezhad; Hossein Motedayyen
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

3.  Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients.

Authors:  Nasr M A Allahloubi; Abdel-Rahman N Zekri; Mohamed Ragab; Marwa Mohanad; Ola S Ahmed; Salem Eid; Mohamed Ghareeb; Iman Gouda; Abeer A Bahnassy
Journal:  Biochem Genet       Date:  2022-02-19       Impact factor: 1.890

Review 4.  Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers.

Authors:  Łukasz Boguszewicz
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

5.  Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.

Authors:  Jing Wu; Ying Yuan; Debra A Long Priel; Danielle Fink; Cody J Peer; Tristan M Sissung; Yu-Ting Su; Ying Pang; Guangyang Yu; Madison K Butler; Tito R Mendoza; Elizabeth Vera; Salman Ahmad; Christine Bryla; Matthew Lindsley; Ewa Grajkowska; Kelly Mentges; Lisa Boris; Ramya Antony; Nancy Garren; Christine Siegel; Nicole Lollo; Christine Cordova; Orwa Aboud; Brett J Theeler; Eric M Burton; Marta Penas-Prado; Heather Leeper; Javier Gonzales; Terri S Armstrong; Katherine R Calvo; William D Figg; Douglas B Kuhns; John I Gallin; Mark R Gilbert
Journal:  Clin Cancer Res       Date:  2021-03-30       Impact factor: 13.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.